Navigation Links
Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Date:5/24/2011

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /PRNewswire/ -- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to enhance the effectiveness of radiotherapy and chemotherapy when treating solid tumors that are hypoxic—or oxygen-starved—and therefore resistant to standard forms of radiotherapy and chemotherapy.

CEN-209 is selectively activated in areas of low oxygen often found within solid tumors.  These areas develop within tumors due to their rapid growth, which impairs the blood vessels bringing nutrients and oxygen, resulting in hypoxia.  

"Hypoxic tumors are generally resistant to radiotherapy and to chemotherapy, and there is no effective treatment for such tumors today," says Thorsten Melcher, PhD, President of Centella Therapeutics.  "Hypoxia occurs in most types of solid tumors, but not necessarily in every patient with a given tumor type. For example, in lung cancer patients, roughly 50 percent of tumors have hypoxic regions.(1)  In the future, successful treatment of hypoxic tumors will likely require identifying affected patients and giving them a hypoxia-specific drug, like CEN-209, in addition to standard treatment."(2)

Radiotherapy works by damaging tumor cells' DNA, but only in well-oxygenated areas, whereas CEN-209 is designed to 'switch on' and damage the DNA only of hypoxic cells, leaving other cells alone," Melcher adds.  "Thus, the two treatment approaches have the potential to complement each other, and CEN-209 is specifically designed to be preferentially used in combination with radiotherapy."

Professor William Wilson and Associate Profes
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
(Date:7/30/2015)... -- ResMed Inc. (NYSE: RMD ) today announced results ... the quarter was $453.1 million, a 9 percent increase ... 17 percent increase on a constant currency basis).  Net ... June 30, 2014.  Diluted earnings per share for the ... 30, 2014.  The results for the ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
(Date:8/1/2015)... ... ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has announced ... donation to kick off the campaign for healing and Well-Being. , BeverlyD has helped ... line of raw, organic hair care products, as well as her book, Hair Now!— ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the ... the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, ... as tried-and-true products that have stood the test of time. These include lighting ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... be removed through the nose using endoscopy rather than having ... this approach, doctors use tiny scopes and cameras to enter ... pulverizes and suctions. At points where the tumor adheres to ... drill is used to eliminate tumor cells in the underlying ...
... Swedish study, Women's Health in the Lund Area, ... of the data collected now reveals a small ... [EHP 113:1627-1631]//. This suggests that low-level cadmium exposure ... general population is likely to encounter low-level chronic ...
... new study, which appears in the October issue ... frequency of and early exposure to severe hypoglycemia ... ,Severe hypoglycemia is a significant and relatively ... type 1 diabetes. Repeated severe hypoglycemia has been ...
... frequently shows a sonographic pattern of ‘pneumonia’//. , ... The acoustic–physical conditions of the thorax produces the most serious ... , ... a method complementary to conventional X-ray examination. The sonographic pattern ...
... Health Minister Anbumani Ramadoss has said that the government is ... and plans to take several steps to check female foeticide, ... ,Dr Ramadoss said that there were plans to set up ... unfortunate practice that prevails on a large scale in the ...
... the first in United Kingdom to perform a Live Liver ... said that in 2006 five live liver operations would be ... live liver regeneration operation a part of liver is transplanted ... the donor and recipient, the regeneration to full size of ...
Cached Medicine News:Health News:Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus 2Health News:The Exposure Of Cadmium And Its Effects On Kidneys 2Health News:Severe Hypoglycemia And Spatial Memory In Children With Type 1 Diabetes 2